Edgar Snyder & Associates®
A Law Firm Representing Injured People
Call Us Toll Free 24/7
Published on Feb 27, 2008 by Edgar Snyder

Anemia Drugs May Increase Risk of Death in Cancer Patients

Anemia Drugs

Aranesp, Epogen, and Procrit – anemia drugs used to boost the number of red blood cells in patients with cancer and kidney disease – have been linked to an increased risk of death. Clinical trial analysis shows that patients treated with these anemia drugs are 10 percent more likely to die than patients taking placebo medication.

To identify the increased risk of fatality, over 50 clinical trials were used to pull data from over 13,600 patients. Along with the heightened risk of death, data also shows that Aranesp, Epogen, and Procrit are 57 percent more likely to cause blood clots in patients.

Aranesp, Epogen, and Procrit are given to cancer patients on chemotherapy and patients with kidney disease in the hopes of avoiding risky blood transfusions. Currently, the Food and Drug Administration has not announced any additional regulatory action on these anemia drugs.

Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Maryland, Ohio, Virginia, and West Virginia, and we associate with experienced attorneys in other states. In addition, all drug-related litigation may involve co-counsel.

Source: "Higher Risks Found for Anemia Drugs." By Jennifer Corbett Dooren. Wall Street Journal. February 27, 2008.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
Briefly describe your injuries

Recent News

Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Sep 16, 2016
Smartphone Apps for Drivers
Sep 16, 2016
New CDC Tool Will Help Keep Traveling Workers Safe
Sep 14, 2016
PA Residents: You're This Much More Likely to Hit a Deer